Mechanisms regulating colorectal cancer cell metastasis into liver (review)

Oncology Letters

Volumn 3, Issue 1, 2012, Pages 11-15

  Jin, Ketao ^a,b,c   Gao, Weili ^b   Lu, Yanyan ^a   Lan, Huanrong ^c   Teng, Lisong ^b   Cao, Feilin ^a  

^a TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; Liver metastasis; Organ selectivity; References

Indexed keywords

ALPHAVBETA5 INTEGRIN; CADHERIN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR6; FIBRONECTIN; GLYPICAN; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; NECTIN 1; NEUTRALIZING ANTIBODY; SOMATOMEDIN C; TETRASPANIN; VASCULOTROPIN; VITRONECTIN RECEPTOR;

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CELL ADHESION; CELL MIGRATION; COLORECTAL CANCER; GENE CONTROL; HUMAN; LIVER METASTASIS; NONHUMAN; PROTEIN EXPRESSION;

EID: 84855215601     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.432     Document Type: Article

References (62)

1. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
2. Fidler IJ: Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 50: 6130-6138, 1990.
3. Chambers AF, Groom AC and MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572, 2002.
4. Fidler IJ: The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458, 2003.
5. Lu X and Kang Y: Organotropism of breast cancer metastasis. J Mammary Gland Biol Neoplasia 12: 153-162, 2007.
6. Horak CE and Steeg PS: Metastasis gets site specific. Cancer Cell 8: 93-95, 2005.
7. Nguyen DX, Bos PD and Massagué J: Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9: 274-284, 2009.
8. Fisher ER and Turnbull RB Jr: The cytologic demonstration and significance of tumor cells in the mesenteric venous blood in patients with colorectal carcinoma. Surg Gynecol Obstet 100: 102-108, 1955.
9. Fisher ER and Fisher B: Experimental studies of factors influencing the development of hepatic metastases. Xiii. Effect of hepatic trauma in parabiotic pairs. Cancer Res 23: 896-900, 1963.
10. Paku S, Döme B, Tóth R and Timár J: Organ-specificity of the extravasation process: an ultrastructural study. Clin Exp Metastasis 18: 481-492, 2000.
11. Lalor PF, Lai WK, Curbishley SM, Shetty S and Adams DH: Human hepatic sinusoidal endothelial cells can be distinguished by expression of phenotypic markers related to their specialised functions in vivo. World J Gastroenterol 12: 5429-5439, 2006.
12. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R and Abbruzzese JL: Metastatic patterns in adenocarcinoma. Cancer 106: 1624-1633, 2006.
13. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA and Massagué J: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549, 2003.
14. Yin J, Pollock C, Tracy K, Chock M, Martin P, Oberst M and Kelly K: Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone. Mol Cell Biol 27: 7538-7550, 2007.
15. Haier J and Nicolson GL: Tumor cell adhesion under hydrodynamic conditions of fluid flow. APMIS 109: 241-262, 2001.
16. Hahn E, Wick G, Pencev D and Timpl R: Distribution of basement membrane proteins in normal and fibrotic human liver: collagen type IV, laminin, and fibronectin. Gut 21: 63-71, 198.
17. Wisse E, Braet F, Luo D, De Zanger R, Jans D, Crabbé E and Vermoesen A: Structure and function of sinusoidal lining cells in the liver. Toxicol Pathol 24: 100-111, 1996.
18. Tamkun JW and Hynes RO: Plasma fibronectin is synthesized and secreted by hepatocytes. J Biol Chem 258: 4641-4647, 1983.
19. Kemperman H, Wijnands YM and Roos E: alphaV Integrins on HT-29 colon carcinoma cells: adhesion to fibronectin is mediated solely by small amounts of alphaVbeta6, and alphaVbeta5 is codistributed with actin fibers. Exp Cell Res 234: 156-164, 1997.
20. Haier J, Nasralla M and Nicolson GL: Different adhesion properties of highly and poorly metastatic HT-29 colon carcinoma cells with extracellular matrix components: role of integrin expression and cytoskeletal components. Br J Cancer 80: 1867-1874, 1999.
21. Kemperman H, Wijnands Y, Meijne AM and Roos E: TA3/St, but not TA3/Ha, mammary carcinoma cell adhesion to hepatocytes is mediated by alpha 5 beta 1 interacting with surface-associated fibronectin. Cell Adhes Commun 2: 45-58, 1994.
22. Roos E, Dingemans KP, Van de Pavert IV and Van den Bergh-Weerman MA: Mammary-carcinoma cells in mouse liver: infiltration of liver tissue and interaction with Kupffer cells. Br J Cancer 38: 88-99, 1978.
23. Trutmann M and Sasse D: The lymphatics of the liver. Anat Embryol (Berl) 190: 201-209, 1994.
24. Nicolson GL: Cancer metastasis: tumor cell and host organ properties important in metastasis to specific secondary sites. Biochim Biophys Acta 948: 175-224, 1988.
25. Eble JA and Haier J: Integrins in cancer treatment. Curr Cancer Drug Targets 6: 89-105, 2006.
26. Gooding JM, Yap KL and Ikura M: The cadherin-catenin complex as a focal point of cell adhesion and signalling: new insights from three-dimensional structures. Bioessays 26: 497-511, 2004.
27. Silbert JE and Sugumaran G: A starting place for the road to function. Glycoconj J 19: 227-237, 2002.
28. Weiss L: Biomechanical interactions of cancer cells with the microvasculature during hematogenous metastasis. Cancer Metastasis Rev 11: 227-235, 1992.
29. Haier J, Nasralla M and Nicolson GL: Cell surface molecules and their prognostic values in assessing colorectal carcinomas. Ann Surg 231: 11-24, 2000.
30. Schlüter K, Gassmann P, Enns A, Korb T, Hemping-Bovenkerk A, Hölzen J and Haier J: Organ-specific metastatic tumor cell adhesion and extravasation of colon carcinoma cells with different metastatic potential. Am J Pathol 169: 1064-1073, 2006.
31. Juliano RL and Varner JA: Adhesion molecules in cancer: the role of integrins. Curr Opin Cell Biol 5: 812-818, 1993.
32. Hulleman E and Boonstra J: Regulation of G1 phase progression by growth factors and the extracellular matrix. Cell Mol Life Sci 58: 80-93, 2001.
33. Kikkawa H, Kaihou M, Horaguchi N, Uchida T, Imafuku H, Takiguchi A, Yamazaki Y, Koike C, Kuruto R, Kakiuchi T, et al: Role of integrin alpha(v)beta3 in the early phase of liver metastasis: PET and IVM analyses. Clin Exp Metastasis 19: 717-725, 2002.
34. Enns A, Korb T, Schlüter K, Gassmann P, Spiegel HU, Senninger N, Mitjans F and Haier J: Alphavbeta5-integrins mediate early steps of metastasis formation. Eur J Cancer 41: 1065-1072, 2005.
35. Enns A, Gassmann P, Schlüter K, Korb T, Spiegel HU, Senninger N and Haier J: Integrins can directly mediate metastatic tumor cell adhesion within the liver sinusoids. J Gastrointest Surg 8: 1049-1059, 2004.
36. Haier J, Nasralla MY and Nicolson GL: Beta1-integrin-mediated dynamic adhesion of colon carcinoma cells to extracellular matrix under laminar flow. Clin Exp Metastasis 17: 377-387, 1999.
37. Okazaki K, Nakayama Y, Shibao K, Hirata K, Nagata N and Itoh H: Enhancement of metastatic activity of colon cancer as influenced by expression of cell surface antigens. J Surg Res 78: 78-84, 1998.
38. Konno A, Hoshino Y, Terashima S, Motoki R and Kawaguchi T: Carbohydrate expression profile of colorectal cancer cells is relevant to metastatic pattern and prognosis. Clin Exp Metastasis 19: 61-70, 2002.
39. Balkwill F: Cancer and the chemokine network. Nat Rev Cancer 4: 540-550, 2004.
40. Erez N and Coussens LM: Leukocytes as paracrine regulators of metastasis and determinants of organ-specific colonization. Int J Cancer 128: 2536-2544, 2011.
41. Kim J, Mori T, Chen SL, Amersi FF, Martinez SR, Kuo C, Turner RR, Ye X, Bilchik AJ, Morton DL and Hoon DS: Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg 244: 113-120, 2006.
42. Günther K, Leier J, Henning G, Dimmler A, Weissbach R, Hohenberger W and Förster R: Prediction of lymph node meta-stasis in colorectal carcinoma by expression of chemokine receptor CCR7. Int J Cancer 116: 726-733, 2005.
43. Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, Foshag L, Bilchik AJ and Hoon DS: Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 23: 2744-2753, 2005.
44. Ottaiano A, di Palma A, Napolitano M, Pisano C, Pignata S, Tatangelo F, Botti G, Acquaviva AM, Castello G, Ascierto PA, et al: Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells. Cancer Immunol Immunother 54: 781-791, 2005.
45. Zeelenberg IS, Ruuls-Van Stalle L and Roos E: The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 63: 3833-3839, 2003.
46. Ghadjar P, Coupland SE, Na IK, Noutsias M, Letsch A, Stroux A, Bauer S, Buhr HJ, Thiel E, Scheibenbogen C and Keilholz U: Chemokine receptor CCR6 expression level and liver metastases in colorectal cancer. J Clin Oncol 24: 1910-1916, 2006.
47. Rubie C, Oliveira V, Kempf K, Wagner M, Tilton B, Rau B, Kruse B, Konig J and Schilling M: Involvement of chemokine receptor CCR6 in colorectal cancer metastasis. Tumour Biol 27: 166-174, 2006.
48. Kitamura T, Fujishita T, Loetscher P, Revesz L, Hashida H, Kizaka-Kondoh S, Aoki M and Taketo MM: Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model. Proc Natl Acad Sci USA 107: 13063-13068, 2010.
49. Coukos G and Rubin SC: Chemotherapy resistance in ovarian cancer: new molecular perspectives. Obstet Gynecol 91: 783-792, 1998.
50. Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi K, Terao Y, Kumano S, Takatsu Y, Masuda Y, et al: Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature 411: 613-617, 2001.
51. Lee JH, Park SR, Chay KO, Seo YW, Kook H, Ahn KY, Kim YJ and Kim KK: KAI1 COOH-terminal interacting tetraspanin (KITENIN), a member of the tetraspanin family, interacts with KAI1, a tumor metastasis suppressor, and enhances metastasis of cancer. Cancer Res 64: 4235-4243, 2004.
52. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B, Romans KE, Choti MA, Lengauer C, Kinzler KW and Vogelstein B: A phosphatase associated with metastasis of colorectal cancer. Science 294: 1343-1346, 2001.
53. Kato H, Semba S, Miskad UA, Seo Y, Kasuga M and Yokozaki H: High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases. Clin Cancer Res 10: 7318-7328, 2004.
54. Zeng Q, Dong JM, Guo K, Li J, Tan HX, Koh V, Pallen CJ, Manser E and Hong W: PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res 63: 2716-2722, 2003.
55. Fiordalisi JJ, Keller PJ and Cox AD: PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility. Cancer Res 66: 3153-3161, 2006.
56. Li J, Guo K, Koh VW, Tang JP, Gan BQ, Shi H, Li HX and Zeng Q: Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases. Clin Cancer Res 11: 2195-2204, 2005.
57. Miyamoto S, Nakamura M, Shitara K, Nakamura K, Ohki Y, Ishii G, Goya M, Kodama K, Sangai T, Maeda H, et al: Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers. Clin Cancer Res 11: 3494-3502, 2005.
58. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, Mass R, Perrou B, Nelson B and Novotny WF: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23: 3697-3705, 2005.
59. Yoo PS, Lopez-Soler RI, Longo WE and Cha CH: Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer 6: 202-207, 2006.
60. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM and Vokes EE: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23: 8033-8040, 2005.
61. Ellis LM, Curley SA and Grothey A: Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 23: 4853-4855, 2005.
62. Yezhelyev MV, Koehl G, Guba M, Brabletz T, Jauch KW, Ryan A, Barge A, Green T, Fennell M and Bruns CJ: Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res 10: 8028-8036, 2004.